Get started
Author

S. Patil

Observed name: S Patil
ORCID: 0009-0002-7841-4599
Observed ORCID: 0009-0002-7841-4599
OpenAlex ID: A5111214041
Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
2014 · P Tan, A Wei, et al. · Blood Cancer Journal · 95
PDF
Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma
2014 · P Campbell, P Walker, et al. · Blood Cancer Journal · 14
PDF
Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients
2013 · A Bryant, I Nivison-Smith, et al. · Bone Marrow Transplantation · 14
An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial
2017 · A Grigg, B Butcher, et al. · Bone Marrow Transplantation · 13
High‐dose cytarabine (24 g/m2) in combination with idarubicin ( HiDAC ‐3) results in high first‐cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia
2012 · M. Low, D. Lee, et al. · Internal Medicine Journal · 11
Health economic impact of high‐dose versus standard‐dose cytarabine induction chemotherapy for acute myeloid leukaemia
2014 · P. L. Fedele, S. Avery, et al. · Internal Medicine Journal · 8
Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma
2017 · A P Nair, P Walker, et al. · Bone Marrow Transplantation · 6
Challenges in performing surveillance for central line associated bacteraemia in haematology‐oncology units
2013 · L. J. Worth, J. Kennon, et al. · Internal Medicine Journal · 4
Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up
2009 · S Patil, A Spencer, et al. · Bone Marrow Transplantation · 4
1879P Effectiveness of intravenous fosnetupitant & palonosetron for cinv prophylaxis in patients receiving highly emetogenic chemotherapy regimens: Subgroup analysis from a phase IV Indian study
2024 · A.K. Verma, A. Pednekar, et al. · Annals of Oncology · 2
PDF
R‐ivac Salvage Therapy in Relapsed and Refractory Dlbcl
2019 · J. Casan, G. Wolyncewicz, et al. · Hematological Oncology · 2
PDF
Safety and Activity of the Highly Specific Btk Inhibitor, Bgb‐3111 Plus Obinutuzumab in Patients (pts) With Follicular Lymphoma (fl) and Chronic Lymphocytic Leukemia (cll)
2017 · C.S. Tam, H. Quach, et al. · Hematological Oncology · 2
PDF
Modifying chemotherapeutic management of a patient with Burkitt's lymphoma and pre-existing motor neurone disease
2015 · H. Bortz, J. Coutsouvelis, et al. · Journal of Clinical Pharmacy and Therapeutics · 2
PDF
Failure of haematopoietic recovery overcome by SCT despite invasive mucormycosis infection
2011 · G Grigoriadis, C C Chang, et al. · Bone Marrow Transplantation · 1
Urinary cytology in multiple myeloma
2007 · S. Patil, A. Schwarer, et al. · Cytopathology · 1
Changes in energy expenditure and body composition following allogeneic stem cell transplant
2024 · I. Nyulasi, Sarah Collins, et al. · Clinical Nutrition ESPEN
Pb2176: an Australian/new Zealand Randomized Trial of Post-transplant Cyclophosphamide in Matched Related Peripheral Blood Stem Cell Transplants for Acute Leukaemia or Myelodysplasia – Allg Bm12
2022 · D. Curtis, S. Patil, et al. · HemaSphere
Hepato-pancreato-biliary malignancies in patients with connective tissue disorders: a United States population based study from national inpatient sample database (1998–2010)
2018 · A. Kandilis, S. Patil, et al. · HPB
Works count: 18
Citation count: 179
H-index: 6
I10-index: 5
Year
Topic
Type